埃沃洛库马布在心血管疾病中的成本效益:系统性审查
Nashmil Ghadimi1, Rajabali Daroudi1, Hosein Shabaninejad2
1Department of Health Management, Policy & Economics, School of Public Health, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Current therapeutic research, clinical and experimental
|October 29, 2024
概括
对于高风险心血管疾病 (CVD) 患者来说,Evolocumab可能具有成本效益,但这取决于疾病类型和风险. 诸如LDL-C水平和药物成本等因素会影响结果.
科学领域:
- 心血管医学 心血管医学
- 卫生经济学 卫生经济学
背景情况:
- 心血管疾病 (CVD) 构成了全球严重的健康负担.
- 具有成本效益的干预措施对于管理心血管疾病至关重要.
- 评估像Evolocumab这样的新疗法的经济影响至关重要.
研究的目的:
- 系统地审查和评估Evolocumab在患有心血管疾病风险的成年人中的成本效益.
- 综合Evolocumab治疗的成本效益分析 (CEA) 的发现.
主要方法:
- 在主要数据库 (Cochrane,EMBASE,PubMed等) 进行了系统的文献搜索. ) 的情况.
- 包括到2023年3月发表的Evolocumab在心血管疾病患者中的CEAs.
- 使用CHEERS标准评估报告质量,并将成本调整为2023美元PPP.
主要成果:
- 审查了16项研究 (2016-2023年),主要来自美国和中国.
- 大多数研究使用了具有终身视界的马尔科夫模型,报告每次质量调整寿命年 (QALY) 和节省寿命年 (LYS) 的增量成本效益比率 (ICER).
- ICER/QALY的范围很大 (从3,342.57美元到2,687,920.13美元),受到LDL-C水平,Evolocumab成本和疾病类型的影响.
结论:
- 埃沃洛库马布显示出潜在的成本效益,特别是在高风险心血管疾病患者中.
- 成本效益因疾病类别,患者风险和评估方法而异.
- 未来的研究应该解决经济影响的不确定性,并考虑不同的收入水平和特定的影响因素.
相关概念视频
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.1K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.1K
01:26Coronary Artery Disease IV: Medical Management
3
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
3
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
558
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
558
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
103
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
103
01:17Ischemic Heart Disease: Overview
1.2K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.2K
01:16Bioequivalence: Overview
926
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
926